These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31306783)

  • 1. CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
    Wise J; Furness M; McWilliams S; Patton S
    Drug Discov Today; 2019 Nov; 24(11):2120-2125. PubMed ID: 31306783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.
    Shimazawa R; Ikeda M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):601-610. PubMed ID: 32064968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union.
    Verbaanderd C; Trullás Jimeno A; Engelbergs J; Zander H; Reischl I; Moreno Oliver A; Vamvakas S; Vleminckx C; Bouygues C; Girard T; Day F; Frias Z
    Clin Pharmacol Ther; 2023 Aug; 114(2):316-324. PubMed ID: 37132507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enterprises and challenges in diagnostics for precision medicine: an interview with Eddie Blair.
    Blair E; Raison C
    Expert Rev Mol Diagn; 2015; 15(12):1521-3. PubMed ID: 26560159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine: what's all the fuss about?
    Barker R
    Scand J Clin Lab Invest Suppl; 2016; 245():S2-5. PubMed ID: 27542001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enabling Precision Oncology Through Precision Diagnostics.
    Brown NA; Elenitoba-Johnson KSJ
    Annu Rev Pathol; 2020 Jan; 15():97-121. PubMed ID: 31977297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics.
    Enzmann H; Meyer R; Broich K
    Biomark Med; 2016 Dec; 10(12):1261-1268. PubMed ID: 27661101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing the genomic revolution in cancer diagnostics.
    Nguyen D; Gocke CD
    Virchows Arch; 2017 Aug; 471(2):175-194. PubMed ID: 28639053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing precision medicine in a global world.
    Rubin EH; Allen JD; Nowak JA; Bates SE
    Clin Cancer Res; 2014 Mar; 20(6):1419-27. PubMed ID: 24634465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
    Campbell MR
    Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Companion and complementary diagnostics for infectious diseases.
    Dailey PJ; Elbeik T; Holodniy M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
    Cowling T; Boucher M
    Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein array-based companion diagnostics in precision medicine.
    Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
    Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the new European Union
    Hermans AMM; Maliepaard M; Boon WPC; Pasmooij AMG
    Expert Rev Mol Diagn; 2022 May; 22(5):583-590. PubMed ID: 35673983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Companion and complementary diagnostics: an important treatment decision tool in precision medicine.
    Jørgensen JT
    Expert Rev Mol Diagn; 2020 Jun; 20(6):557-559. PubMed ID: 32342707
    [No Abstract]   [Full Text] [Related]  

  • 18. Implementing the EU in vitro diagnostic regulation - a European regulatory perspective on companion diagnostics.
    Ritzhaupt A; Hayes I; Ehmann F
    Expert Rev Mol Diagn; 2020 Jun; 20(6):565-567. PubMed ID: 31976775
    [No Abstract]   [Full Text] [Related]  

  • 19. Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.
    Furtado LV; Samowitz WS
    Virchows Arch; 2017 Aug; 471(2):235-242. PubMed ID: 28551725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the clinical implementation of precision medicine companion diagnostics.
    Keeling P; Clark J; Finucane S
    Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.